These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
425 related articles for article (PubMed ID: 27095464)
21. [Comprehensive treatment of neuroblastoma in children associated with opsoclonus-myoclonus-ataxia syndrome]. Zhao W; Sun Q; Xie Y; Hua Y; Xiong H; Jia J; Lu X Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):540-3. PubMed ID: 25224062 [TBL] [Abstract][Full Text] [Related]
30. [Clinical diagnosis and therapy of opsoclonus-myoclonus syndrome]. Xiong H; Peng J; Zhang YH; Bao XH; Jiang YW; Qin J Zhonghua Er Ke Za Zhi; 2008 Aug; 46(8):570-3. PubMed ID: 19099827 [TBL] [Abstract][Full Text] [Related]
31. A nationwide survey of opsoclonus-myoclonus syndrome in Japanese children. Hasegawa S; Matsushige T; Kajimoto M; Inoue H; Momonaka H; Oka M; Ohga S; Ichiyama T; Brain Dev; 2015 Aug; 37(7):656-60. PubMed ID: 25454391 [TBL] [Abstract][Full Text] [Related]
32. Autoantibody-mediated cytotoxicity in paediatric opsoclonus-myoclonus syndrome is dependent on ERK-1/2 phophorylation. Fühlhuber V; Bick S; Tschernatsch M; Dharmalingam B; Kaps M; Preissner KT; Blaes F J Neuroimmunol; 2015 Dec; 289():182-6. PubMed ID: 26616889 [TBL] [Abstract][Full Text] [Related]
33. Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective. Rossor T; Yeh EA; Khakoo Y; Angelini P; Hemingway C; Irani SR; Schleiermacher G; Santosh P; Lotze T; Dale RC; Deiva K; Hero B; Klein A; de Alarcon P; Gorman MP; Mitchell WG; Lim M; Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35260471 [TBL] [Abstract][Full Text] [Related]
34. Monocentric retrospective clinical outcome in a group of 13 patients with opsoclonus myoclonus syndrome, proposal of diagnostic algorithm and review of the literature. Urtiaga Valle S; Souvannanorath S; Leboucq N; Haouy S; Rivier F; Roubertie A; Meyer P Eur J Paediatr Neurol; 2022 Sep; 40():18-27. PubMed ID: 35926472 [TBL] [Abstract][Full Text] [Related]
35. Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses. Ertle F; Behnisch W; Al Mulla NA; Bessisso M; Rating D; Mechtersheimer G; Hero B; Kulozik AE Pediatr Blood Cancer; 2008 Mar; 50(3):683-7. PubMed ID: 17226843 [TBL] [Abstract][Full Text] [Related]
36. An unusual case of opsoclonus-myoclonus-ataxia syndrome associated neuroblastoma: High-risk disease requiring immunotherapy. Stiefel J; Basu E; Meyer R; Kaur G; Khakoo Y Pediatr Blood Cancer; 2020 Nov; 67(11):e28393. PubMed ID: 32798258 [No Abstract] [Full Text] [Related]
37. Serum IgG-induced microglial activation enhances neuronal cytolysis via the NO/sGC/PKG pathway in children with opsoclonus-myoclonus syndrome and neuroblastoma. Ding X; Yang W; Ren Q; Hu J; Yang S; Han W; Wang J; Wang X; Wang H J Neuroinflammation; 2020 Jun; 17(1):190. PubMed ID: 32546235 [TBL] [Abstract][Full Text] [Related]
38. Effect of Increased Immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS). Mitchell WG; Wooten AA; O'Neil SH; Rodriguez JG; Cruz RE; Wittern R J Child Neurol; 2015 Jul; 30(8):976-82. PubMed ID: 25342308 [TBL] [Abstract][Full Text] [Related]
40. Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up. Catsman-Berrevoets CE; Aarsen FK; van Hemsbergen ML; van Noesel MM; Hakvoort-Cammel FG; van den Heuvel-Eibrink MM Pediatr Blood Cancer; 2009 Dec; 53(6):1048-53. PubMed ID: 19672966 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]